Zhai Ya-Ling, Zhu Li, Shi Su-Fang, Liu Li-Jun, Lv Ji-Cheng, Zhang Hong
Renal Division, Department of Medicine, Peking University First Hospital, Beijing, China; Peking University Institute of Nephrology, Beijing, China; Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China; Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, Beijing, China.
PLoS One. 2014 Jul 9;9(7):e101779. doi: 10.1371/journal.pone.0101779. eCollection 2014.
Endothelial injury, which may present clinically as hypertension, proteinuria and increased von Willebrand Factor (vWF) level, is a common manifestation in IgA nephropathy (IgAN). However, causal factors for endothelial injury in IgAN are not completely understood. An imbalance of vascular endothelial growth factor/Soluble fms-like tyrosine kinase-1 (VEGF/sFlt-1) has been observed in many diseases with endothelial dysfunction, including pre-eclampsia and diabetic retinopathy, but whether it contributes to endothelial injury in IgAN requires further exploration.
Initially, 96 IgAN patients and 22 healthy volunteers were enrolled as a discovery cohort. VEGF/sFlt-1, sFlt-1 and VEGF levels were compared between patients with IgAN and healthy volunteers to explore the underlying factors that contribute to endothelial injury in IgAN. The identified contributor (sFlt-1) was further confirmed in a replication cohort, which included 109 IgAN patients and 30 healthy volunteers. Correlations of sFlt-1 with hypertension, proteinuria, Oxford-E score and plasma vWF were further evaluated in the combined 205 patients with IgAN.
VEGF/sFlt-1 levels were significantly lower in IgAN patients than healthy volunteers (0.33±0.27 vs. 0.43±0.22, p = 0.02) in the discovery cohort. Within the ratio, plasma sFlt-1 levels were significantly elevated (101.18±25.19 vs. 79.73±18.85 pg/ml, p<0.001), but plasma VEGF levels showed no significant differences. Elevated sFlt-1 levels in the replication cohort were confirmed in IgAN patients (93.40±39.78 vs. 71.92±15.78 pg/ml, p<0.001). Plasma sFlt-1 levels in IgAN patients correlated with proteinuria (severe (>3.5 g/d) vs. moderate (1-3.5 g/d) vs. mild (<1 g/d) proteinuria: 115.95±39.09 vs. 99.89±28.55 vs. 83.24±33.92 pg/ml; severe vs. mild: p<0.001, moderate vs. mild p = 0.001, severe vs. moderate: p = 0.014), hypertension (with vs. without hypertension: 107.87±31.94 vs. 87.32±32.76 pg/ml, p = 0.015) and vWF levels (r = 0.161, p = 0.021).
The present study found elevated sFlt-1 in IgAN patients and further identified its correlation with proteinuria, hypertension and vWF levels. These results suggested that elevated sFlt-1 contributes to endothelial injury in IgAN.
内皮损伤在IgA肾病(IgAN)中较为常见,临床上可能表现为高血压、蛋白尿和血管性血友病因子(vWF)水平升高。然而,IgAN中内皮损伤的病因尚未完全明确。在包括子痫前期和糖尿病视网膜病变在内的许多伴有内皮功能障碍的疾病中,均观察到血管内皮生长因子/可溶性fms样酪氨酸激酶-1(VEGF/sFlt-1)失衡,但它是否导致IgAN中的内皮损伤尚需进一步探究。
最初,纳入96例IgAN患者和22名健康志愿者作为发现队列。比较IgAN患者与健康志愿者的VEGF/sFlt-1、sFlt-1和VEGF水平,以探究导致IgAN内皮损伤的潜在因素。在一个复制队列(包括109例IgAN患者和30名健康志愿者)中进一步证实所确定的因素(sFlt-1)。在205例合并的IgAN患者中进一步评估sFlt-1与高血压、蛋白尿、牛津-E评分和血浆vWF的相关性。
在发现队列中,IgAN患者的VEGF/sFlt-1水平显著低于健康志愿者(0.33±0.27对0.43±0.22,p = 0.02)。在该比值中,血浆sFlt-1水平显著升高(101.18±25.19对79.73±18.85 pg/ml,p<0.001),但血浆VEGF水平无显著差异。复制队列中IgAN患者sFlt-1水平升高得到证实(93.40±39.78对71.92±15.78 pg/ml,p<0.001)。IgAN患者的血浆sFlt-1水平与蛋白尿(重度(>3.5 g/d)对中度(1 - 3.5 g/d)对轻度(<1 g/d)蛋白尿:115.95±39.09对99.89±28.55对83.24±33.92 pg/ml;重度对轻度:p<0.001,中度对轻度p = 0.001,重度对中度:p = 0.014)、高血压(有高血压对无高血压:107.87±31.94对87.32±32.76 pg/ml,p = 0.015)和vWF水平(r = 0.161,p = 0.021)相关。
本研究发现IgAN患者sFlt-1升高,并进一步确定其与蛋白尿、高血压和vWF水平相关。这些结果表明sFlt-1升高导致IgAN中的内皮损伤。